Kobayashi Pharmaceutical Co Ltd
TSE:4967
Intrinsic Value
Kobayashi Pharmaceutical Co., Ltd. engages in the manufacture and sale of over-the-counter (OTC) pharmaceuticals, quasi-drugs, air fresheners, and sanitary products. [ Read More ]
The intrinsic value of one
Kobayashi Pharmaceutical Co Ltd
stock under the Base Case scenario is
7 553.47
JPY.
Compared to the current market price of 5 543 JPY,
Kobayashi Pharmaceutical Co Ltd
is
Undervalued by 27%.
Kobayashi Pharmaceutical Co Ltd's market capitalization is 412.1B JPY.
Kobayashi Pharmaceutical Co Ltd stock price is 5 543 JPY.
Kobayashi Pharmaceutical Co Ltd stock price (5543 JPY) is 27% less than its Intrinsic Value (7 553.47 JPY).
Kobayashi Pharmaceutical Co Ltd stock price (5543 JPY) is 40% less than its DCF Value (9 168.29 JPY). Open DCF Valuation
Kobayashi Pharmaceutical Co Ltd stock price (5543 JPY) is 7% less than its Relative Value (5 938.65 JPY). Open Relative Valuation
Kobayashi Pharmaceutical Co Ltd has upside potential of 51% compared to the average analyst price target.
Open Wall St Estimates
Kobayashi Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
Kobayashi Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 10%.
Kobayashi Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 11% to 10%.
Kobayashi Pharmaceutical Co Ltd's Revenue has grown by 4% over the past 12 months.
Kobayashi Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
Kobayashi Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Kobayashi Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 16% to 13%.
Kobayashi Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
Kobayashi Pharmaceutical Co Ltd's Revenue has been growing by 5% per year for the last 3 years.
Kobayashi Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Kobayashi Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 15%. The company is efficient at using invested capital to generate operating income.
Kobayashi Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Kobayashi Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Kobayashi Pharmaceutical Co Ltd's short-term assets (158B JPY) exceed its short-term liabilties (56B JPY).
Kobayashi Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.
Kobayashi Pharmaceutical Co Ltd's long-term assets (267B JPY) exceed its long-term liabilties (63B JPY).
Kobayashi Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (80B JPY) than debt (608m JPY).
Kobayashi Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 6.98.
Kobayashi Pharmaceutical Co Ltd earns more than enough operating income (26B JPY) to safely cover interest payments on its debt (22m JPY).
Valuation Backtest
Kobayashi Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Kobayashi Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Kobayashi Pharmaceutical Co Ltd
Balance Sheet Decomposition
Kobayashi Pharmaceutical Co Ltd
| Current Assets | 158.3B |
| Cash & Short-Term Investments | 79.8B |
| Receivables | 53B |
| Other Current Assets | 25.5B |
| Non-Current Assets | 109.1B |
| Long-Term Investments | 34.8B |
| PP&E | 47.7B |
| Intangibles | 21.6B |
| Other Non-Current Assets | 5.1B |
| Current Liabilities | 56.1B |
| Accounts Payable | 17.3B |
| Accrued Liabilities | 3.5B |
| Other Current Liabilities | 35.3B |
| Non-Current Liabilities | 6.5B |
| Long-Term Debt | 608m |
| Other Non-Current Liabilities | 5.9B |
Earnings Waterfall
Kobayashi Pharmaceutical Co Ltd
|
Revenue
|
173.5B
JPY
|
|
Cost of Revenue
|
-77.1B
JPY
|
|
Gross Profit
|
96.4B
JPY
|
|
Operating Expenses
|
-70.6B
JPY
|
|
Operating Income
|
25.8B
JPY
|
|
Other Expenses
|
-5.4B
JPY
|
|
Net Income
|
20.3B
JPY
|
Free Cash Flow Analysis
Kobayashi Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Kobayashi Pharmaceutical Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Kobayashi Pharmaceutical Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kobayashi Pharmaceutical Co Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
Kobayashi Pharmaceutical Co Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kobayashi Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Kobayashi Pharmaceutical Co Ltd
is 8 375.48 JPY
with a low forecast of 6 605.4 JPY and a high forecast of 10 920 JPY.
Shareholder Return
Price
Kobayashi Pharmaceutical Co Ltd
| Average Annual Return | 3.14% |
| Standard Deviation of Annual Returns | 25.73% |
| Max Drawdown | -61% |
| Market Capitalization | 412.1B JPY |
| Shares Outstanding | 74 338 896 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kobayashi Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Kobayashi Pharmaceutical Co., Ltd. engages in the manufacture and sale of over-the-counter (OTC) pharmaceuticals, quasi-drugs, air fresheners, and sanitary products. The company is headquartered in Osaka, Osaka-Fu and currently employs 3,451 full-time employees. The firm operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
Kobayashi Pharmaceutical Co Ltd
stock under the Base Case scenario is
7 553.47
JPY.
Compared to the current market price of 5 543 JPY,
Kobayashi Pharmaceutical Co Ltd
is
Undervalued by 27%.
You don't have any saved screeners yet
